Stay updated with breaking news from Bayesian Optimal Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on...
27.09.2023 - Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. ... Seite 1
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial... -Today at 08:11 am- MarketScreener
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer
BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.